Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $58.9 million.

  • Vanda Pharmaceuticals' Shares Outstanding (Diluted Average) rose 134.32% to $58.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $58.9 million, marking a year-over-year increase of 134.32%. This contributed to the annual value of $58.9 million for FY2025, which is 134.32% up from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $58.9 million for Q4 2025, which was up 134.32% from $59.1 million recorded in Q3 2025.
  • Vanda Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $59.1 million during Q3 2025, with a 5-year trough of $56.1 million in Q1 2022.
  • For the 5-year period, Vanda Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $57.6 million, with its median value being $57.5 million (2023).
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Shares Outstanding (Diluted Average) skyrocketed by 331.78% in 2021, and later crashed by 70.76% in 2022.
  • Vanda Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $56.9 million in 2021, then rose by 0.11% to $57.0 million in 2022, then rose by 1.01% to $57.6 million in 2023, then grew by 1.03% to $58.1 million in 2024, then rose by 1.34% to $58.9 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $58.9 million in Q4 2025, compared to $59.1 million in Q3 2025 and $59.0 million in Q2 2025.